Biogen (BIIB) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Biogen Revenue Highlights

Latest Revenue (Y)

$9.68B

Latest Revenue (Q)

$2.47B

Main Segment (Y)

MS Product Revenues

Main Geography (Y)

Non-US

Biogen Revenue by Period

Biogen Revenue by Year

Date	Revenue	Change
2024-12-31	$9.68B	-1.62%
2023-12-31	$9.84B	-3.32%
2022-12-31	$10.17B	-7.36%
2021-12-31	$10.98B	-18.32%
2020-12-31	$13.44B	-6.49%
2019-12-31	$14.38B	6.88%
2018-12-31	$13.45B	9.61%
2017-12-31	$12.27B	7.21%
2016-12-31	$11.45B	6.36%
2015-12-31	$10.76B	10.93%
2014-12-31	$9.70B	39.97%
2013-12-31	$6.93B	25.66%
2012-12-31	$5.52B	9.27%
2011-12-31	$5.05B	7.04%
2010-12-31	$4.72B	7.75%
2009-12-31	$4.38B	6.83%
2008-12-31	$4.10B	29.19%
2007-12-31	$3.17B	69.41%
2006-12-31	$1.87B	9.25%
2005-12-31	$1.71B	7.38%
2004-12-31	$1.60B	134.96%
2003-12-31	$679.18M	-40.86%
2002-12-31	$1.15B	10.06%
2001-12-31	$1.04B	12.62%
2000-12-31	$926.45M	16.62%
1999-12-31	$794.43M	42.48%
1998-12-31	$557.59M	28.46%
1997-12-31	$434.04M	56.64%
1996-12-31	$277.09M	82.67%
1995-12-31	$151.69M	-2.98%
1994-12-31	$156.34M	14.62%
1993-12-31	$136.40M	-

Biogen generated $9.68B in revenue during NA 2024, up -1.62% compared to the previous quarter, and up 67.30% compared to the same period a year ago.

Biogen Revenue by Quarter

Date	Revenue	Change
2024-09-30	$2.47B	4.79%
2024-06-30	$2.35B	6.94%
2024-03-31	$2.20B	-7.79%
2023-12-31	$2.39B	-5.69%
2023-09-30	$2.53B	3.03%
2023-06-30	$2.46B	-0.28%
2023-03-31	$2.46B	-3.18%
2022-12-31	$2.54B	1.42%
2022-09-30	$2.51B	-3.11%
2022-06-30	$2.59B	2.26%
2022-03-31	$2.53B	-7.39%
2021-12-31	$2.73B	-1.62%
2021-09-30	$2.78B	0.14%
2021-06-30	$2.77B	3.01%
2021-03-31	$2.69B	-5.56%
2020-12-31	$2.85B	-15.51%
2020-09-30	$3.38B	-8.30%
2020-06-30	$3.68B	4.17%
2020-03-31	$3.53B	-3.73%
2019-12-31	$3.67B	1.98%
2019-09-30	$3.60B	-0.46%
2019-06-30	$3.62B	3.64%
2019-03-31	$3.49B	-1.04%
2018-12-31	$3.53B	2.54%
2018-09-30	$3.44B	2.46%
2018-06-30	$3.36B	7.20%
2018-03-31	$3.13B	-5.32%
2017-12-31	$3.31B	7.45%
2017-09-30	$3.08B	-0.02%
2017-06-30	$3.08B	9.52%
2017-03-31	$2.81B	-2.13%
2016-12-31	$2.87B	-2.84%
2016-09-30	$2.96B	2.13%
2016-06-30	$2.89B	6.14%
2016-03-31	$2.73B	-3.96%
2015-12-31	$2.84B	2.21%
2015-09-30	$2.78B	7.19%
2015-06-30	$2.59B	1.44%
2015-03-31	$2.55B	-3.25%
2014-12-31	$2.64B	5.15%
2014-09-30	$2.51B	3.72%
2014-06-30	$2.42B	13.70%
2014-03-31	$2.13B	8.34%
2013-12-31	$1.97B	7.55%
2013-09-30	$1.83B	6.05%
2013-06-30	$1.72B	21.79%
2013-03-31	$1.42B	-37.80%
2012-12-31	$2.27B	107.23%
2012-09-30	$1.10B	-22.74%
2012-06-30	$1.42B	9.98%
2012-03-31	$1.29B	-2.62%
2011-12-31	$1.33B	1.28%
2011-09-30	$1.31B	8.38%
2011-06-30	$1.21B	0.44%
2011-03-31	$1.20B	-1.29%
2010-12-31	$1.22B	3.68%
2010-09-30	$1.18B	-3.04%
2010-06-30	$1.21B	9.36%
2010-03-31	$1.11B	-1.61%
2009-12-31	$1.13B	0.58%
2009-09-30	$1.12B	2.49%
2009-06-30	$1.09B	5.48%
2009-03-31	$1.04B	-3.03%
2008-12-31	$1.07B	-2.20%
2008-09-30	$1.09B	10.02%
2008-06-30	$993.44M	5.44%
2008-03-31	$942.19M	5.47%
2007-12-31	$893.30M	-

Biogen generated $2.47B in revenue during Q3 2024, up 4.79% compared to the previous quarter, and up 100.40% compared to the same period a year ago.

Biogen Revenue Breakdown

Biogen Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
Interferon	$968.00M	$1.31B	-	-	-
MS Product Revenues	$4.35B	$5.43B	-	-	-
SPINRAZA	$1.57B	$1.79B	-	-	-
TYSABRI product	$1.72B	$2.03B	-	-	-
Fumarate	$1.60B	$2.00B	-	-	-
Royalty	-	$67.40M	$27.90M	$33.90M	$17.00M
Product	-	$7.99B	-	-	-
Revenues from anti-cd20 therapeutic programs	-	$1.70B	-	-	-
Product and Service, Other	-	$485.10M	$18.20M	$48.60M	$383.20M
Other corporate revenues	-	-	$427.70M	$719.10M	$584.50M

Biogen's latest annual revenue breakdown by segment (product or service), as of Dec 24: MS Product Revenues (42.64%), TYSABRI product (16.81%), Fumarate (15.64%), SPINRAZA (15.42%), and Interferon (9.49%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Jun 24	Mar 24	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Fumarate	$404.40M	$390.90M	$418.00M	$381.80M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interferon	$236.00M	$237.50M	$250.90M	$243.60M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
TYSABRI product	$415.40M	$406.10M	$462.20M	$431.30M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
MS Product Revenues	$1.07B	$1.05B	$1.15B	$1.08B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SPINRAZA	$421.40M	$381.40M	$429.10M	$341.30M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenues from anti-cd20 therapeutic programs	-	-	-	$394.00M	$433.40M	$399.50M	$447.90M	$416.90M	$436.30M	$399.40M	$414.10M	$415.40M	$440.00M	$389.00M	$419.00M	$560.10M	$478.30M	$520.40M	$600.80M	$595.80M
Product	-	-	-	$1.71B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product and Service, Other	-	-	-	$184.60M	$197.50M	$319.10M	$191.60M	$129.50M	$97.90M	$66.10M	$126.20M	$157.80M	$99.00M	$93.30M	$132.00M	$125.70M	$407.60M	$109.30M	$145.70M	$109.60M
Royalty	-	-	-	-	$14.40M	$12.20M	$8.80M	$10.30M	$7.60M	$7.70M	$6.40M	$6.20M	$5.10M	$10.30M	$7.10M	$11.40M	$7.10M	$3.30M	-	-
Other corporate revenues	-	-	-	-	-	-	-	$114.20M	$81.20M	$113.60M	$143.80M	$87.10M	$83.20M	$119.60M	$110.00M	$395.50M	$94.00M	$122.10M	$93.10M	-

Biogen's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: MS Product Revenues (42.01%), SPINRAZA (16.54%), TYSABRI product (16.31%), Fumarate (15.88%), and Interferon (9.26%).

Biogen Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
UNITED STATES	$2.19B	$3.47B	$1.14B	$1.10B	$5.50M
Non-US	$3.98B	$920.90M	$849.30M	$850.40M	-
GERMANY	-	$926.20M	$1.16B	-	-
Segment Geographical Groups Of Countries Group Other	-	$64.00M	$61.80M	$80.30M	$78.30M
Asia	-	$672.10M	-	-	-
Europe	-	$2.40B	$100.00K	$200.00K	-
Europe, Excluding Germany	-	$100.00K	-	-	-

Biogen's latest annual revenue breakdown by geography, as of Dec 24: Non-US (64.48%), and UNITED STATES (35.52%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Jun 24	Mar 24	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Non-US	$1.00B	$956.40M	$1.05B	$965.80M	$15.90M	$14.70M	$12.50M	$9.90M	$6.90M	$236.30M	$224.70M	$241.70M	$224.40M	$230.00M	$204.40M	$212.30M	$187.90M	$244.70M	$203.40M	$220.60M
UNITED STATES	-	$813.00M	$846.70M	$746.10M	$130.30M	$93.50M	$138.30M	$127.90M	$129.90M	$284.50M	$288.00M	$281.10M	$299.80M	$273.30M	$270.80M	$304.20M	$244.10M	$277.70M	$269.50M	$263.00M

Biogen's latest quarterly revenue breakdown by geography, as of Dec 24: Non-US (100.00%).

Biogen Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
MRK	Merck	$64.17B	$16.66B
PFE	Pfizer	$63.63B	$17.70B
JNJ	Johnson & Johnson	$61.35B	$22.47B
BMY	Bristol-Myers Squibb	$48.30B	$11.89B
NVS	Novartis	$46.66B	$11.83B
SNY	Sanofi	$43.07B	$11.12B
AMGN	Amgen	$33.42B	$8.50B
GSK	GSK	$30.33B	$7.36B
GILD	Gilead Sciences	$28.75B	$7.55B
BIIB	Biogen	$9.68B	$2.47B
ABBV	AbbVie	-	$14.46B

BIIB Revenue FAQ

What is Biogen’s yearly revenue?

Biogen's yearly revenue for 2024 was $9.68B, representing a decrease of -1.62% compared to 2023. The company's yearly revenue for 2023 was $9.84B, representing a decrease of -3.32% compared to 2022. BIIB's yearly revenue for 2022 was $10.17B, representing a decrease of -7.36% compared to 2021.

What is Biogen’s quarterly revenue?

Biogen's quarterly revenue for Q3 2024 was $2.47B, a 4.79% increase from the previous quarter (Q2 2024), and a -2.55% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $2.35B, a 6.94% increase from the previous quarter (Q1 2024), and a -4.19% decrease year-over-year (Q2 2023). BIIB's quarterly revenue for Q1 2024 was $2.2B, a -7.79% decrease from the previous quarter (Q4 2023), and a -10.67% decrease year-over-year (Q1 2023).

What is Biogen’s revenue growth rate?

Biogen's revenue growth rate for the last 3 years (2022-2024) was -4.89%, and for the last 5 years (2020-2024) was -28.03%.

What are Biogen’s revenue streams?

Biogen's revenue streams in c 24 are Interferon, MS Product Revenues, SPINRAZA, TYSABRI product, and Fumarate. Interferon generated $968M in revenue, accounting 9.49% of the company's total revenue, down -25.85% year-over-year. MS Product Revenues generated $4.35B in revenue, accounting 42.64% of the company's total revenue, down -19.90% year-over-year. SPINRAZA generated $1.57B in revenue, accounting 15.42% of the company's total revenue, down -12.28% year-over-year. TYSABRI product generated $1.72B in revenue, accounting 16.81% of the company's total revenue, down -15.55% year-over-year. Fumarate generated $1.6B in revenue, accounting 15.64% of the company's total revenue, down -20.14% year-over-year.

What is Biogen’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Biogen was MS Product Revenues. This segment made a revenue of $4.35B, representing 42.64% of the company's total revenue.